Fig. 4: Her2-PI3K pathway gene alterations were detected in KRAS-G12C inhibitor plus cetuximab combination-resistant PDCs. | npj Precision Oncology

Fig. 4: Her2-PI3K pathway gene alterations were detected in KRAS-G12C inhibitor plus cetuximab combination-resistant PDCs.

From: Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization

Fig. 4

a Genomic profiling of KRAS-mutated PDCs. Genomic DNA (gDNA) was purified from surgically resected clinical samples, and NGS was executed using 108 cancer-related gene-focused libraries. OncoPlot revealed alterations of the indicated gene (left) in each sample (bottom). b CNV alterations of JC261 cells. The copy ratio was analyzed by CNVkit using target re-sequencing data in Fig. 4a and visualized in the ERBB2 region. c Confirmation of Her2 expression and PI3K signaling. Cell lysates were immunoblotted to detect the indicated antibodies (left).

Back to article page